Fig. 5

IPD synergizes with anti-PD1 treatment in breast cancer. A EO771 (left) and 4T1 (right) tumor growth treated with vehicle, IPD, anti-PD1, or IPD + anti-PD1 (n = 5, two-way ANOVA). B Kaplan-Meir survival analysis of 4T1 tumor-bearing mice with indicated treatments (n = 10, log-rank test). C Lung metastatic nodules from 4T1 tumor-bearing mice treated with indicated treatments (n = 5, one-way ANOVA). D Quantification of CD8⁺ T cells ratios in EO771 and 4T1 tumors treated with indicated treatments (n = 5, one-way ANOVA). E, F Representative flow cytometry images and percentages of IFN-γ⁺ CD8⁺ T cells from EO771 (E) and 4T1 (F) tumors (n = 5, one-way ANOVA). Mean ± SEM; * p < 0.05; ** p < 0.01; *** p < 0.001